A research team led by City University of Hong Kong (CityU) has found a shortcut for developing new drugs which can potentially reduce time and costs by sorting out high potential candidates out of a long list of chemical compounds, with an accuracy of around 50%. This breakthrough in neuropharmacology came following five years of collaborated research by CityU’s Department of Biomedical Engineering (BME) and Department of Biomedical Sciences (BMS), and Harvard Medical School.
A novel way to edit the genome of disease-carrying mosquitoes that brings us closer to suppressing them on a continental scale has been developed by the researchers at the University of California, Berkeley (UC Berkeley). The study used CRISPR/Cas9 gene-editing technology to insert and spread genes designed to suppress wild insects, while at the same time avoiding the resistance to these efforts that evolution would typically favor. The proof-of-concept study was demonstrated in fruit flies; but the researchers believe this technology could be used in mosquitoes to help fight malaria and other mosquito-borne diseases in the next decade, pending public and regulatory approval.
X-ZELL is a global biotechnology company aiming to fundamentally reshuffle the way of diagnosing and managing one of the most pressing health issues of the time – cancer (lat. Carcinoma). The company was founded in 2014 in Singapore. Ranked among Asia’s 20 most innovative health technology start-ups, X-ZELL has developed a new platform technology capable of detecting tumour-derived Circulating Endothelial Cells (tCEC) in a small, 10mL blood sample. Long considered ‘undetectable’ in clinical routine, these ultra-rare cells help physicians diagnose clinically significant cancer early when it can be cured – in turn avoiding more than 70% of unnecessary interventions and saving billions to health systems worldwide.
Researchers at The University of Texas at Dallas (UTDallas) have designed genetic 'circuits' out of living cellular material in order to gain a better understanding of how proteins function, with the goal of making improvements. Tyler Quarton, a bioengineering graduate student, and Dr. Leonidas Bleris, associate professor of bioengineering in the Erik Jonsson School of Engineering and Computer Science, hope their work has a big impact on synthetic biology and gene therapy. Every living cell contains a compilation of genes, which serves as the blueprint for all the biological activity within a cell. The team explains this system by comparing genes to musicians.
An experimental drug, similar to compounds used to treat diabetes, that slows the progression of Parkinson’s disease itself - as well as its symptoms - in mice has been developed by the researchers at Johns Hopkins University School of Medicine. In experiments performed with cultures of human brain cells and live mouse models, they report the drug blocked the degradation of brain cells that is the hallmark of Parkinson’s disease (lat. Parkinson scriptor morbus). The drug is expected to move to clinical trials last year. If planned clinical trials for the drug, named NLY01, are successful in humans, it could be one of the first treatments to directly target the progression of Parkinson’s disease, not just the muscle rigidity, spasmodic movements, fatigue, dizziness, dementia and other symptoms of the disorder.
3B BlackBio Biotech India Limited is one of the leading Indian companies in the field of PCR based Molecular Diagnostic Kits. The company was established in 2011 as Indo-Spanish JV company and engaged in design, development, manufacturing and commercialization of PCR based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents. The PCR based Molecular Diagnostic Kits are commercialized with TRUPCR® brand to renowned diagnostics labs across the country. TRUPCR® is a registered trademark of 3B BlackBio Biotech India Limited.